Abstract:Cellular senescence describes an irreversible growth arrest characterized by distinct morphology, gene expression pattern, and secretory phenotype. The final or intermediate stages of senescence can be reached by different genetic mechanisms and in answer to different external and internal stresses. It has been maintained in the literature but never proven by clearcut experiments that the induction of senescence serves the evolutionary purpose of protecting the individual from development and growth of cancers. This hypothesis was recently scrutinized by new experiments and found to be partly true, but part of the gene activities now known to happen in senescence are also needed for cancer growth, leading to the view that senescence is a double-edged sword in cancer development. In current cancer therapy, cellular senescence is, on the one hand, intended to occur in tumor cells, as thereby the therapeutic outcome is improved, but might, on the other hand, also be induced unintentionally in non-tumor cells, causing inflammation, secondary tumors, and cancer relapse. Importantly, organismic aging leads to accumulation of senescent cells in tissues and organs of aged individuals. Senescent cells can occur transiently, e.g., during embryogenesis or during wound healing, with beneficial effects on tissue homeostasis and regeneration or accumulate chronically in tissues, which detrimentally affects the microenvironment by de- or transdifferentiation of senescent cells and their neighboring stromal cells, loss of tissue specific functionality, and induction of the senescence-associated secretory phenotype, an increased secretory profile consisting of pro-inflammatory and tissue remodeling factors. These factors shape their surroundings toward a pro-carcinogenic microenvironment, which fuels the development of aging-associated cancers together with the accumulation of mutations over time. We are presenting an overview of well-documented stress situations and signals, which induce senescence. Among them, oncogene-induced senescence and stress-induced premature senescence are prominent. New findings about the role of senescence in tumor biology are critically reviewed with respect to new suggestions for cancer therapy leveraging genetic and pharmacological methods to prevent senescence or to selectively kill senescent cells in tumors.

Cellular Aging and Senescence in Cancer: A Holistic Review of Cellular Fate Determinants.

Common Pathogenetic Mechanisms Underlying Aging and Tumor and Means of Interventions.

Cellular senescence in cancer: molecular mechanisms and therapeutic targets

Targeting Senescent Cells and Tumor Therapy (Review)

Cellular Senescence: Mechanisms and Therapeutic Potential

Cellular Senescence and Anti-Cancer Therapy.

Cellular senescence: a double-edged sword in cancer therapy

The dual role of cellular senescence in human tumor progression and therapy

A Review of Celluar Senescence and Tumor Treatment

Cellular Senescence and Tumor Therapy

Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression

Cellular Senescence, Frailty, and Possible Opportunities for Interventions

Cellular senescence in cancer: clinical detection and prognostic implications

Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment

Cancer‐associated fibroblasts under therapy‐induced senescence in the tumor microenvironment (Review)

Cellular senescence: Molecular mechanisms and pathogenicity

Senescence and cancer — role and therapeutic opportunities

The Paradoxical Role of Cellular Senescence in Cancer

The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy

Therapeutic strategies targeting cellular senescence for cancer and other diseases